(VIANEWS) – The NASDAQ opens in less than five hours and Xenetic Biosciences‘s pre-market value is already 10.85% down.

Xenetic Biosciences’s last close was $0.45, 64.08% below its 52-week high of $1.25.

The last session, NASDAQ ended with Xenetic Biosciences (XBIO) rising 2.09% to $0.45. NASDAQ jumped 1.79% to $11,926.24, following the last session’s upward trend on what was an all-around positive trend trading session.

About Xenetic Biosciences

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.85%.


Today’s last reported volume for Xenetic Biosciences is 30610 which is 83.03% below its average volume of 61338.

Revenue Growth

Year-on-year quarterly revenue growth grew by 18.6%, now sitting on 1.55M for the twelve trailing months.

Moving Average

Xenetic Biosciences’s worth is way under its 50-day moving average of $0.51 and way under its 200-day moving average of $0.59.

More news about Xenetic Biosciences (XBIO).